In a bid to protect sales for its human growth hormone drug Genotropin, Pfizer licensed rights to a longer-lasting human growth hormone therapy, hGH-CTP, in December. This longer-lasting drug has just ...
A Pfizer drug for growth hormone deficiency has bounced back from an FDA rejection to finally win regulatory approval, clearing the way for the pharmaceutical giant to compete against a smaller rival ...
NEW YORK, April 2 (Reuters) - Pfizer Inc. on Monday said it had agreed to pay almost $35 million in fines to settle federal charges that a rival drugmaker it acquired four years ago had ...
NEW YORK & MIAMI--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) and OPKO Health Inc. (NASDAQ: OPK) announced today that the U.S. Food and Drug Administration (FDA) has approved NGENLA (somatrogon-ghla), a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback